LJI Available Technologies

La Jolla Institute FOR IMMUNOLOGY | Life Without Disease.®

Anti-SARS-CoV-2 Spike Antibodies

Researchers at the La Jolla Institute for Immunology have isolated and sequenced human memory B cells that produce antibodies targeting the Spike protein of SARS-CoV-2. These antibodies may be useful in saliva-based diagnostic tests or as basic research tools. They may also be useful for the design of therapeutics for the prevention or treatment of SARS-CoV-2.

The worldwide spread of SARS-CoV-2 in the human population has resulted in the ongoing COVID-19 pandemic and has already caused more than 491 million infections and more than 6.2 million deaths resulting from SARS-CoV-2 or related diseases and conditions. As such, effective countermeasures against the emergence and expansion of SARS-CoV-2 are required. Such effective countermeasures include the development of new tools for detection, diagnosis, monitoring, and treatment.

As such, researchers at LJI have isolated and sequenced SARS-CoV-2 antibodies from human memory B cells. These antibodies specifically target the Spike protein of SARS-CoV-2, and they may be useful in diagnostic tests, as basic research tools, or for the design of therapeutics that prevent and/or treat COVID-19 disease.

ADVANTAGES:

- **Useful for in saliva-based diagnostic tests**
- **Useful as basic research tools**
- **Useful for the design of therapeutics for the prevention/treatment of SARS-CoV-2**

Anti-SARS-CoV-2 Spike Antibodies Isolated from Human Memory B Cells



Neutralization curves of SARS-CoV-2 antibodies by the Spike protein antibodies

Tech ID # 2021-101 Patent Pending

La Jolla Institute for Immunology | Business Development
+1 (858) 752-6500
bd@lji.org
https://www.lji.org/research/licensing-opportunities/